Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade - Shukla, Sachet A.; Bachireddy, Pavan; Schilling, Bastian; Galonska, Christina; Zhan, Qian; Bango, Clyde; Langer, Rupert; Lee, Patrick C.; Gusenleitner, Daniel; Keskin, Derin B.; Babadi, Mehrtash; Mohammad, Arman; et al. (Cell, 2018)
Keywords: Animals; Antibodies, Monoclonal - therapeutic use; antigens; Antigens, Neoplasm - genetics; Antigens, Neoplasm - immunology; Autophagy; cancer-germline antigen; Cell Line, Tumor; checkpoint blockade; chromosomes; CTLA-4; CTLA-4 Antigen - genetics; CTLA-4 Antigen - immunology; DNA Methylation; Epigenesis, Genetic; Female; gene expression; Gene Expression Profiling; Germ-Line Mutation; Humans; immunogenomics; Immunotherapy; ipilimumab; Ipilimumab - pharmacology; MAGE-A; Male; melanoma; Melanoma - genetics; Melanoma - immunology; Melanoma-Specific Antigens - genetics; Melanoma-Specific Antigens - immunology; metastasis; Mice; Mice, Transgenic; Neoplasms - genetics; Neoplasms - immunology; patients; PD-1; protein content; Skin Neoplasms - genetics; Skin Neoplasms - immunology; therapeutics; ubiquitin-protein ligase; immunogenomics; checkpoint blockade; cancer-germline antigen; autophagy; ipilimumab; immunotherapy; melanoma; CTLA-4; MAGE-A; PD-1